查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1499969

全球寡核甘酸合成市场评估：依产品、类型、应用、最终用户、地区、机会、预测（2017-2031）

Oligonucleotide Synthesis Market Assessment, By Product, By Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 233 Pages | 商品交期: 3-5个工作天内

价格

全球寡核甘酸合成市场规模预计将从 2023 年的 60.6 亿美元增至 2031 年的 187.6 亿美元，2024-2031 年预测期间复合年增长率为 15.17%。市场成长的推动因素包括製药和生物技术领域研发投资的增加、各公司之间的合作和伙伴关係的增加、慢性病的流行以及法医和基因检测和研究活动中使用的定制寡核甘酸的需求。

增加研发投入是寡核甘酸合成市场的全球主要趋势。2023 年 9 月，西班牙领先的製药公司之一 Insud Pharma Group 在 Chemo India Formulation Private Limited 开设了寡核甘酸中心。该研究和生产中心将专注于寡核甘酸的商业生产和研究。该设施已通过Drug Control Center of India、Spanish Health Agency和美国FDA（食品药物协会）的检查和批准。

新产品和新技术的推出为市场提供了利润丰厚的成长机会。2024 年 4 月，Asahi Kasei Bioprocess Inc.推出了最新的 Olio 製造创新产品 THESYS ACS ERGO 合成柱。此色谱柱减少了转换时间，同时保持了产品品质和用户安全。THESYS ACS ERGO 旨在透过其易于操作的设计实现安全、平稳的转换并减少批次间的低效率。THESYS ACS ERGO 的省时功能是透过在维护和更换过程中消除螺栓的使用来实现的。

併购支持市场拓展

支持市场成长的是全球各地区不断增加的併购和联盟。这些活动使公司能够成功地进行研究合作，并确保先进技术的发现、交付和开发。併购帮助公司有机扩张，提供必要的资金来推动研发活动以及新疗法和技术的开发，并支持全球寡核甘酸合成市场的成长。

2024 年 6 月，GSK plc 宣布以 5,000 万美元收购 Elsie Biotechnologies, LLC，以开发寡核甘酸疗法的潜力。寡核甘酸具有调节基因表现的独特能力，并有可能解决小分子生物製剂和分子无法实现的广泛治疗标靶。Elsie 专注于优化寡核甘酸治疗的递送、降低毒性和提高疗效。透过收购Elsie，GSK可望加强在基因调控方面的研发力道。此外，GSK 对工具学习和人工智慧的使用，与 Elsie 平台的数据相结合，预计将支援预测模型的开发，以简化未来的寡核甘酸设计。

诊断应用的增加推动市场成长

由于各种疾病和病症的流行，对寡核甘酸的需求不断增加，这增强了全球对寡核甘酸合成的需求。对于研究和诊断应用，寡核甘酸是使用多孔玻璃 (CPG) 合成的。在分子生物学中，寡核甘酸可用于使用杂交测定和聚合□炼式反应检测感兴趣的 RNA 和 DNA 序列。基于寡核甘酸的微阵列已被开发用于分析不同细胞类型和组织中的基因表现水平，且寡核甘酸探针可用于识别与遗传疾病相关的多态性和特定突变。越来越多的遗传性疾病患者增加了对用于诊断干预的寡核甘酸的需求。Epilepsy Foundation估计，每 20,000 至 40,000 人中就有 1 人患有 Dravet 症候群。

本报告研究和分析了全球寡核甘酸合成市场，提供市场规模和预测、市场动态以及主要参与者的现状和前景。

目录

第1章 研究方法论

第2章 专案范围与定义

第3章 执行摘要

第4章 全球寡核甘酸合成市场展望（2017-2031）

  • 市场规模及预测
    • 金额
  • 依产品
    • 寡核甘酸
    • 机器
    • 试剂
  • 依类型
    • 客製化寡核甘酸
    • 预先设计的寡核甘酸
  • 依用途
    • 治疗
    • 诊断
    • 研究
  • 依最终用户
    • 製药公司、生技公司
    • 诊断实验室
    • 学术研究所
    • 医院
  • 依地区
    • 北美
    • 南美洲
    • 欧洲
    • 亚太地区
    • 中东/非洲
  • 市场占有率：依公司划分（2023 年）

第5章 全球寡核甘酸合成市场展望：依地区（2017-2031）

  • 北美
    • 市场规模及预测
    • 依产品
    • 依类型
    • 依用途
    • 依最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 南美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第6章 市场测绘（2023）

  • 依产品
  • 依类型
  • 依用途
  • 依最终用户
  • 依地区

第7章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第8章 市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第9章 监理架构与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/新技术

第10章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT 分析（5 家市场公司）
  • 专利分析（如果适用）

第11章 案例研究

第12章 主要公司展望

  • Thermo Fisher Scientific Inc.
  • Merck & Co., Inc.
  • Agilent Technologies, Inc.
  • Eurofins Scientific SE
  • Bio-Synthesis, Inc.
  • Danaher Corporation
  • KANEKA CORPORATION
  • Sarepta Therapeutics, Inc.
  • Biogen Inc.
  • GenScript Biotech Corporation

第13章 战略建议

第14章 关于我们公司、免责声明

Product Code: MX11507

Global oligonucleotide synthesis market is projected to witness a CAGR of 15.17% during the forecast period 2024-2031F, growing from USD 6.06 billion in 2023 to USD 18.76 billion in 2031F. The market's growth is supported by the increasing investments towards research and development activities in the pharmaceutical and biotechnology sectors, rising collaborations and partnerships among various companies, growing prevalence of chronic diseases, and rising demand for custom oligonucleotides for use in forensics, genetic testing, and research activities.

Rising research and development investments are a major global trend in the oligonucleotide synthesis market. In September 2023, Insud Pharma Group, one of the leading Spanish pharmaceutical companies, inaugurated its oligonucleotide center at Chemo India Formulation Private Limited. The research and production center will focus on commercial production and research on oligonucleotides. The facility was inspected and approved by the Drug Control Center of India, Spanish Health Agency, and the US FDA (United States Food and Drug Association).

Introducing novel products and technologies provides lucrative growth opportunities to the market. In April 2024, Asahi Kasei Bioprocess Inc. unveiled their latest olio manufacturing innovation, the THESYS ACS ERGO synthesis column, which offers reduced changeover time while maintaining the quality of the product and maintaining user safety. The THESYS ACS ERGO facilitates a safe and smooth changeover between runs with the help of its operator-friendly design and is engineered to reduce inefficiencies between batches. The time-saving feature of the THESYS ACS ERGO is achieved by eliminating the utilization of threaded bolts in the maintenance and changeover process.

Mergers and Acquisitions are Supporting Market Expansion

The growth of the market is supported by the rising mergers and acquisitions and successful collaborations in various regions across the globe. These activities allow companies to follow through with successful research collaborations and ensure the discovery, delivery, and development of advanced technologies. Mergers and acquisitions aid in the company's organic expansion and provide necessary funds for driving research and development activities and development of novel therapies and technologies, thus bolstering the global oligonucleotide synthesis market growth.

In June 2024, GSK plc announced the acquisition of Elsie Biotechnologies, LLC for USD 50 million to capitalize on the potential of oligonucleotide therapeutics. The unique ability of the oligonucleotides to modulate gene expressions makes them a potential modality for addressing a wide range of therapeutic targets that might not be amenable to small biologics and molecules. Elsie is focused on optimizing delivery, reducing toxicity, and enhancing the potency of oligonucleotide therapeutics. With the acquisition of Elsie, GSK is expected to enhance its research and development efforts in gene modulation. Furthermore, the utilization of machine learning and artificial intelligence by GSK, in combination with the data from Elsie's platform, is expected to support the development of predictive models for streamlining future oligonucleotide designs.

Rising Applications in Diagnostics Bolsters the Market Growth

The rising demand for oligonucleotides due to the growing prevalence of various diseases and disorders is bolstering the global demand for oligonucleotide synthesis. For research and diagnostic applications, oligonucleotides are synthesized using controlled pore glass (CPG). In molecular biology, oligonucleotides aid in detecting the desired RNA and DNA sequences using hybridization assays and polymerase chain reactions. The oligonucleotide-based microarrays have been developed to analyze the gene expression levels in various cell types and tissues, and oligonucleotide probes can be used to identify polymorphisms and specific mutations associated with genetic disorders. The rise in the number of cases of genetic disorders is thus bolstering the demand for oligonucleotides for diagnostic interventions. According to the estimates of the epilepsy foundation, 1 in 20,000 to 1 in 40,000 individuals have Dravet Syndrome.

Therapeutics Segment to Account for Significant Global Oligonucleotide Synthesis Market Share

The growth of the segment is aided by the rising prevalence of chronic diseases and increasing utilization of oligonucleotides in drug development processes. Over the past few years' oligonucleotides have demonstrated the ability to provide patients with major therapeutic benefits, future developments are expected to boost the expansion of the segment. The segment's growth is supported by the rise in the number of collaborations to support the discovery and development of oligonucleotide therapeutics. In May 2024, Orbit Discovery Ltd. and Secarna Pharmaceuticals GmbH & Co. entered in a collaboration for developing peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics. The collaboration aims to expand Secarna's reach of antisense approaches and strengthen their ability of creating targeted antisense therapeutics, allowing them to offer novel treatment solutions for a wide range of diseases.

Additionally, the growth of the market is supported by the rising investments in companies that are focused on the development of targeted oligonucleotide therapeutics. In January 2022, Ceptur Therapeutics, Inc. announced the completion of a USD 75 million Series A financing. The biotechnology company focuses on the development of targeted oligonucleotide therapeutics that are based on U1 Adaptor Technology. Such investments are expected to support the development of novel products, propelling the expansion of the segment.

North America Accounts for Significant Market Share

The factors supporting the market's growth in North America include rising investments towards the development of advanced therapeutic solutions, rapid expansion of the healthcare and pharmaceutical sectors, and increasing prevalence of various chronic diseases. According to the estimates of the National Cancer Institute, approximately 2,001,140 cases of cancer and 611,720 deaths from the disease are expected to occur in the United States in 2024.

The growing emphasis on novel product development coupled with rising approvals from the US FDA further supports the market expansion. In June 2024, the FDA approved Geron Corporation's RYTELO (imetelstat), an oligonucleotide telomerase inhibitor for treating adults with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) that have transfusion-dependent anemia and require four or more units of red blood cells over eight weeks. Approval was given based on the safety and efficacy findings from the placebo-controlled, randomized, phase 3 IMerge trial.

Furthermore, rising investments in the development of oligonucleotide manufacturing facilities are supporting the expansion of the market in North America. In November 2023, Integrated DNA Technologies, Inc. opened its new therapeutic oligonucleotide manufacturing facility in Iowa, the United States. The site manufactures gene therapy reagents and cGMP cells, including donor oligos for homology-directed repair and sgRNAs (single guide RNAs).

Future Market Scenario (2024 - 2031F)

The potential applications for oligonucleotide synthesis are expected to expand over the forecast period, from gene regulation to gene editing and personalized medicine, novel applications of oligonucleotide synthesis are anticipated to emerge. Future applications and innovations are expected to increasingly focus on personalized medicines and the designing of oligonucleotides that are capable of targeting specific genomic regions or mutations, strengthening the possibility of developing therapies tailored to specific patient requirements, thus facilitating the growth of the market in the forecast period.

Furthermore, the rise in the number of research activities that use oligonucleotides as interventions or treatments is expected to support the expansion of the market in the coming years. The University College London (UCL) is conducting an interventional study, which is expected to conclude in August 2025, to assess if the drug NIO752 reduces the production of tau protein by the brain. In normal conditions tau is responsible for stabilizing neuronal microtubules, however in Alzheimer's the protein builds up in the brain and causes damage.

Key Players Landscape and Outlook

The rising investments by companies across the globe towards developing oligonucleotide manufacturing facilities is expected to boost the global oligonucleotide synthesis market size. Companies are increasingly focusing on forming strategic partnerships and alliances to support such development activities. In April 2024, Axolabs Gmbh and Asahi Kasei Bioprocess Inc. (AKB), part of the Asahi Kasei Group, announced a partnership to build a cGMP manufacturing facility in Berlin to accelerate the commercialization and development of oligonucleotide-based therapies.

Such investments are increasing as oligonucleotide therapies offer targeted approaches for protein production and gene expression modulation and can potentially treat a broad range of diseases. At present, the FDA has approved eighteen oligonucleotide drugs.

Additionally, the market's growth is supported by the rising investments by the key market players in oligonucleotide manufacturing suites. In March 2024, Merck announced the opening of its first cGMP Oligonucleotide Manufacturing suite in Missouri, the United States. The development is expected to enhance the company's oligo offerings to include cGMP quality oligos tailored for clinical and diagnostic markets.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Oligonucleotide Synthesis Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. By Product
    • 4.2.1. Oligonucleotides
      • 4.2.1.1. DNA
        • 4.2.1.1.1. Array-based
        • 4.2.1.1.2. Column-based
      • 4.2.1.2. RNA
        • 4.2.1.2.1. Technology
          • 4.2.1.2.1.1. Array-based
          • 4.2.1.2.1.2. Column-based
        • 4.2.1.2.2. Type
          • 4.2.1.2.2.1. CRISPR (sgRNA)
          • 4.2.1.2.2.2. Short RNA Oligos
          • 4.2.1.2.2.3. Long RNA Oligos
    • 4.2.2. Equipment
    • 4.2.3. Reagents
  • 4.3. By Type
    • 4.3.1. Customized Oligos
    • 4.3.2. Predesigned Oligos
  • 4.4. By Application
    • 4.4.1. Therapeutics
    • 4.4.2. Diagnostics
    • 4.4.3. Research
  • 4.5. By End-user
    • 4.5.1. Pharmaceutical and Biotechnology Company
    • 4.5.2. Diagnostic Laboratories
    • 4.5.3. Academic Research Institutes
    • 4.5.4. Hospitals
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. South America
    • 4.6.3. Europe
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Oligonucleotide Synthesis Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
    • 5.1.2. By Product
      • 5.1.2.1. Oligonucleotides
        • 5.1.2.1.1. DNA
          • 5.1.2.1.1.1. Array-based
          • 5.1.2.1.1.2. Column-based
        • 5.1.2.1.2. RNA
          • 5.1.2.1.2.1. Technology
          • 5.1.2.1.2.1.1. Array-based
          • 5.1.2.1.2.1.2. Column-based
          • 5.1.2.1.2.2. Type
          • 5.1.2.1.2.2.1. CRISPR (sgRNA)
          • 5.1.2.1.2.2.2. Short RNA Oligos
          • 5.1.2.1.2.2.3. Long RNA Oligos
      • 5.1.2.2. Equipment
      • 5.1.2.3. Reagents
    • 5.1.3. By Type
      • 5.1.3.1. Customized Oligos
      • 5.1.3.2. Predesigned Oligos
    • 5.1.4. By Application
      • 5.1.4.1. Therapeutics
      • 5.1.4.2. Diagnostics
      • 5.1.4.3. Research
    • 5.1.5. By End-user
      • 5.1.5.1. Pharmaceutical and Biotechnology Company
      • 5.1.5.2. Diagnostic Laboratories
      • 5.1.5.3. Academic Research Institutes
      • 5.1.5.4. Hospitals
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
        • 5.1.6.1.1. By Value
      • 5.1.6.2. By Product
        • 5.1.6.2.1. Oligonucleotides
          • 5.1.6.2.1.1. DNA
          • 5.1.6.2.1.1.1. Array-based
          • 5.1.6.2.1.1.2. Column-based
          • 5.1.6.2.1.2. RNA
          • 5.1.6.2.1.2.1. Technology
          • 5.1.6.2.1.2.1.1. Array-based
          • 5.1.6.2.1.2.1.2. Column-based
          • 5.1.6.2.1.2.2. Type
          • 5.1.6.2.1.2.2.1. CRISPR (sgRNA)
          • 5.1.6.2.1.2.2.2. Short RNA Oligos
          • 5.1.6.2.1.2.2.3. Long RNA Oligos
        • 5.1.6.2.2. Equipment
        • 5.1.6.2.3. Reagents
      • 5.1.6.3. By Type
        • 5.1.6.3.1. Customized Oligos
        • 5.1.6.3.2. Predesigned Oligos
      • 5.1.6.4. By Application
        • 5.1.6.4.1. Therapeutics
        • 5.1.6.4.2. Diagnostics
        • 5.1.6.4.3. Research
      • 5.1.6.5. By End-user
        • 5.1.6.5.1. Pharmaceutical and Biotechnology Company
        • 5.1.6.5.2. Diagnostic Laboratories
        • 5.1.6.5.3. Academic Research Institutes
        • 5.1.6.5.4. Hospitals
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Type
  • 6.3. By Application
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Case Studies

12. Key Players Outlook

  • 12.1. Thermo Fisher Scientific Inc.
    • 12.1.1. Company Details
    • 12.1.2. Key Management Personnel
    • 12.1.3. Products and Services
    • 12.1.4. Financials (As reported)
    • 12.1.5. Key Market Focus and Geographical Presence
    • 12.1.6. Recent Developments
  • 12.2. Merck & Co., Inc.
  • 12.3. Agilent Technologies, Inc.
  • 12.4. Eurofins Scientific SE
  • 12.5. Bio-Synthesis, Inc.
  • 12.6. Danaher Corporation
  • 12.7. KANEKA CORPORATION
  • 12.8. Sarepta Therapeutics, Inc.
  • 12.9. Biogen Inc.
  • 12.10. GenScript Biotech Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

13. Strategic Recommendations

14. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 3. Global Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Oligonucleotide Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 8. North America Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 9. North America Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 10. North America Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 11. North America Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Oligonucleotide Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 14. United States Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 15. United States Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 16. United States Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 17. United States Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Canada Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 20. Canada Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 21. Canada Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 22. Canada Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Mexico Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 25. Mexico Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 26. Mexico Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 27. Mexico Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Europe Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 30. Europe Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 31. Europe Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 32. Europe Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Oligonucleotide Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Germany Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 36. Germany Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 37. Germany Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 38. Germany Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 40. France Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 41. France Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 42. France Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 43. France Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Italy Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 46. Italy Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 47. Italy Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 48. Italy Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. United Kingdom Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 51. United Kingdom Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 52. United Kingdom Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 53. United Kingdom Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 55. Russia Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 56. Russia Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 57. Russia Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 58. Russia Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Netherlands Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 61. Netherlands Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 62. Netherlands Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 63. Netherlands Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Spain Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 66. Spain Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 67. Spain Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 68. Spain Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Turkey Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 71. Turkey Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 72. Turkey Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 73. Turkey Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Poland Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 76. Poland Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 77. Poland Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 78. Poland Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 80. South America Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 81. South America Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 82. South America Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 83. South America Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Oligonucleotide Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 86. Brazil Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 87. Brazil Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 88. Brazil Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 89. Brazil Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Argentina Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 92. Argentina Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 93. Argentina Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 94. Argentina Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 97. Asia-Pacific Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 98. Asia-Pacific Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 99. Asia-Pacific Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Oligonucleotide Market Share (%), By Country, 2017-2031F
  • Figure 101. India Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. India Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 103. India Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 104. India Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 105. India Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. China Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 108. China Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 109. China Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 110. China Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 112. Japan Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 113. Japan Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 114. Japan Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 115. Japan Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 117. Australia Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 118. Australia Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 119. Australia Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 120. Australia Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 122. Vietnam Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 123. Vietnam Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 124. Vietnam Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 125. Vietnam Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. South Korea Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 128. South Korea Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 129. South Korea Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 130. South Korea Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Indonesia Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 133. Indonesia Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 134. Indonesia Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 135. Indonesia Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 137. Philippines Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 138. Philippines Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 139. Philippines Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 140. Philippines Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 143. Middle East & Africa Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 144. Middle East & Africa Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 145. Middle East & Africa Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Oligonucleotide Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 149. Saudi Arabia Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 150. Saudi Arabia Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 151. Saudi Arabia Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 153. UAE Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 154. UAE Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 155. UAE Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 156. UAE Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Oligonucleotide Market, By Value, In USD Billion, 2017-2031F
  • Figure 158. South Africa Oligonucleotide Market Share (%), By Product, 2017-2031F
  • Figure 159. South Africa Oligonucleotide Market Share (%), By Type, 2017-2031F
  • Figure 160. South Africa Oligonucleotide Market Share (%), By Application, 2017-2031F
  • Figure 161. South Africa Oligonucleotide Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023